The Immune Response Corporation Appoints Robert E. Knowling, Jr. as Ch

    Business Editors/Biotech Writers
    BIOWIRE2K


    CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 10, 2005--The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announces that Robert E. Knowling, Jr. has joined the Company's Board of Directors as Chairman. Mr. Knowling may be best known for his career in telecommunications, including positions with Indiana Bell, Ameritech, US West and Covad. He is a nationally known leader in corporate management and currently serves on the Board of Directors of the Hewlett-Packard Company and Heidrick & Struggles International, Inc., among others.
    "We welcome Bob to lead our Board and are excited about this new era for The Immune Response Corporation. Bob is a nationally recognized expert in strategic planning, capital development and management, and this expertise will be invaluable to us," said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation. "Bob's experience, business acumen and vision will be especially important as we move toward late-stage development and commercialization of our lead products for HIV and MS. Working closely together we will move this Company forward."
    "I am looking forward to working with the impressive management and scientific teams at The Immune Response Corporation. This company has come a long way in the last few years, and I believe its focus on immune-based therapies for treating HIV and MS can have a real impact on human health. I am honored to be able to play a part in the development of these immune-based therapies and help bring them to the patients who so desperately need them," said Mr. Knowling.
    James B. Glavin, who has served as Chairman of the Company's Board of Directors since May 1993, will leave the board later this year.
    As a lead architect of the Ameritech's re-engineering transformation, Mr. Knowling reported directly to the chairman; and was named vice president of Network Operations in 1994. He then joined US WEST in March 1996 as vice president of Network Operations and in 1997 became EVP of Operations & Technology. In July 1998, he joined Covad Communications, a provider of Digital Subscriber Line (DSL) services to homes and small business customers, as chairman, president and chief executive officer. While at Covad, Mr. Knowling was responsible for day-to-day operations, building strategic relationships and all aspects of the company's national roll-out as the network was built to deliver DSL across the United States. He was instrumental in taking the company public in January 1999 and helped quickly scale the company to be able to deliver DSL nationwide as Covad became the leading national DSL provider. After Mr. Knowling left Covad in 2001, market forces compelled the company to reorganize in Federal bankruptcy proceedings.
    In January 2003, Mr. Knowling joined the New York City Department of Education as Chief Executive Officer of their Leadership Academy, which is chartered with developing the next generation of principals in the New York City Public School System; currently undergoing a major transformation. The Leadership Academy is funded by the Partnership for NYC, the Wallace Foundation, The Broad Foundation, and the NYC business community.
    Mr. Knowling serves on the board of directors for Hewlett-Packard Company; Ariba, Inc.; and Heidrick & Struggles International, Inc. He is also a member of the advisory boards for Ontologent, Inc.; Northwestern University's Kellogg Graduate School of Management; and the University of Michigan Graduate School of Business.
    Mr. Knowling earned a Bachelor of Arts degree from Wabash College and a Master of Business Administration degree from Northwestern University's Kellogg Graduate School of Business.

    About The Immune Response Corporation

    The Immune Response Corporation (Nasdaq:IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company's HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.
    The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax(TM), which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.

    Please visit The Immune Response Corporation at www.imnr.com

    This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), NeuroVax(TM)or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE(R), NeuroVax(TM)or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R), NeuroVax(TM)or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2003, and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

    REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

--30--CB/la*

CONTACT: The Immune Response Corporation Michael K. Green, 760-431-7080 info@imnr.com or Sam Brown Inc. Corporate Communication Laura Silver, 310-551-9940 silver@sambrown.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MEDICAL MANAGEMENT CHANGES SOURCE: The Immune Response Corporation

Copyright Business Wire 2005